ID   65FSDNC2
AC   CVCL_RH68
SY   DOX4 hiPSC
DR   SKIP; SKIP001180
DR   Wikidata; Q54604401
RX   PubMed=27089514;
CC   Donor information: Established from a breast cancer patient who received doxorubicin but did not experience cardiotoxicity.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   66Y
CA   Induced pluripotent stem cell
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 7
//
RX   PubMed=27089514; DOI=10.1038/nm.4087; PMCID=PMC5086256;
RA   Burridge, Paul Weisley
RA   Li, Yong Fuga
RA   Matsa, Elena
RA   Wu, Hao-Di
RA   Ong, Sang-Ging
RA   Sharma, Arun
RA   Holmstrom, Alexandra
RA   Chang, Alex C.
RA   Coronado, Michael J.
RA   Ebert, Antje D.
RA   Knowles, Joshua Wiley
RA   Telli, Melinda L.
RA   Witteles, Ronald M.
RA   Blau, Helen Margaret
RA   Bernstein, Daniel
RA   Altman, Russ Biagio
RA   Wu, Joseph C.
RT   "Human induced pluripotent stem cell-derived cardiomyocytes
RT   recapitulate the predilection of breast cancer patients to
RT   doxorubicin-induced cardiotoxicity.";
RL   Nat. Med. 22:547-556(2016).
//